Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX-A12 with radiotherapy-based regimens in first-line MGMT-unmethylated glioblastoma
2024-510964-21-00Phase 2Authorised
- Sponsor
- TME Pharma
- Start
- Sep 2019
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaptesed pegol in glioblastoma (GBM) (9 arms), sponsored by TME Pharma. Primary endpoint: Safety. Planned start Sep 2019; status: authorised.
02
Drugs
olaptesed pegol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-510964-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510964-21-00.